Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: Are they appropriate and safe? [10]

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 6, 2003, Pages 2112-2113

  Aledort, Louis M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; HEART INFARCTION; HEART SURGERY; HUMAN; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOSIS;

EID: 0347694926     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.06.004     Document Type: Letter

References (5)

1. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002;124:852-4.
2. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83-90.
3. Aledort LM. rVIIa-its thrombogenicity [letter]. Thromb Haemost. 2000;84:522-3.
4. Schneiderman J, Nugent DJ, Young G. Combination therapy with activated prothrombin complex concentrate (APCC) and recombinant factor VIIa (rFVIIa) in patients with severe hemophilia and inhibitors. Blood. 2002;100:696a.
5. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost. 2002;88:60-5.